Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,205 public trials 1,002 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069

Conditions
Adnexal Diseases, Advanced Solid Tumor, Bladder Cancer, +72 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California, San Diego (UCSD) - Moores Cancer Center La Jolla, California, United States
  • UCLA Department of Medicine-Hematology/Oncology Los Angeles, California, United States
  • Sarah Cannon Research Institute at HealthOne Denver, Colorado, United States
View all 38 locations
View Trial Details
Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Smilow Cancer Center at Yale-New Haven ( Site 3253) New Haven, Connecticut, United States
  • Billings Clinic ( Site 3255) Billings, Montana, United States
  • NHO Revive Research Institute, LLC ( Site 3218) Lincoln, Nebraska, United States
  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207) Reno, Nevada, United States
View all 42 locations
View Trial Details
Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06095583

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Limited-stage Small Cell Lung Cancer (LS-SCLC), +8 more
Locations
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Xiangya Hospital Central South University Changsha, Hunan, China
  • The Second Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China
  • The First Hospital of China Medical University Shenyang, Liaoning, China
View all 76 locations
View Trial Details
Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • ClinRé 001-022 (Premier Cancer Care and Infusion Center) Fresno, California, United States
  • OPN Healthcare, Inc. Glendale, California, United States
  • University of California Irvine Irvine, California, United States
  • Sutter Health Roseville, California, United States
View all 199 locations
View Trial Details
Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Local Institution - 0170 Athens, Georgia, United States
  • Local Institution - 0034 Lexington, Kentucky, United States
  • Local Institution - 0171 Lexington, Kentucky, United States
  • Local Institution - 0123 Baltimore, Maryland, United States
View all 71 locations
View Trial Details
Recruiting

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Ironwood Cancer and Research Center /ID# 276370 Chandler, Arizona, United States
  • University of Arkansas for Medical Sciences /ID# 272923 Little Rock, Arkansas, United States
  • Valkyrie Clinical Trials /ID# 271322 Los Angeles, California, United States
  • Yale New Haven Hospital /ID# 271584 New Haven, Connecticut, United States
View all 80 locations
View Trial Details
Recruiting

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

NCT04429087

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
Locations
  • Winship Cancer Institute Atlanta, Georgia, United States
  • University of Maryland School of Medicine Baltimore, Maryland, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States
View Trial Details
Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Instituto Alexander Fleming ( Site 0310) Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • Sanatorio Parque ( Site 0311) Rosario, Santa Fe Province, Argentina
  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0306) CABA, Argentina
  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309) CABA, Argentina
View all 72 locations
View Trial Details

Related conditions